DEA Bans Designer Xanax Knockoff With Ridiculous Name
Published Date: 12/15/2025
Proposed Rule
Summary
Starting December 15, 2025, bromazolam—a drug similar to some strong sedatives—will be temporarily placed in Schedule I, meaning it’s considered very risky and illegal to make, sell, or use without special permission. This affects anyone who handles bromazolam, including makers, sellers, researchers, and users, who will now face strict rules and penalties. The move aims to keep people safe by controlling this drug quickly while the government studies it more.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Bromazolam moved to Schedule I
The Drug Enforcement Administration intends to temporarily place bromazolam in Schedule I. When the temporary order is published, persons who handle bromazolam — including manufacture, distribution, import, export, or possession — will be subject to the regulatory controls and administrative, civil, and criminal sanctions that apply to Schedule I substances.
Researchers and labs face Schedule I rules
Researchers, laboratories, and instructors who engage in research, instructional activities, or chemical analysis of bromazolam will be subject to Schedule I regulatory controls and the same administrative, civil, and criminal sanctions. This change takes effect when the temporary scheduling order is published (the order will not be issued before January 14, 2026).
Temporary listing lasts two years (±1 year)
The temporary Schedule I placement will take effect on the date the temporary scheduling order is published in the Federal Register (the order will not be issued before January 14, 2026). The temporary placement will remain in effect for two years and may be extended for one additional year if regular scheduling proceedings are initiated.
Temporary orders not subject to judicial review
Temporary scheduling orders under 21 U.S.C. 811(h) are not subject to judicial review. That means affected parties cannot immediately seek court review of the temporary placement of bromazolam while the order is in effect.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-22756, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities-August 2025
The EPA just announced new requests to change rules about pesticide leftovers on foods like fruits and veggies. Farmers, food makers, and shoppers should pay attention because these changes could affect what’s allowed on your food. You’ve got until January 14, 2026, to share your thoughts before any decisions are made!
Next: 2025-22775, Income of Foreign Governments and of International Organizations
The IRS is proposing new rules to clarify when foreign governments’ earnings from U.S. investments count as business income and when they control companies doing business here. These changes mainly affect foreign governments earning money in the U.S. and could impact how their income is taxed. Comments on the proposal are open until February 13, 2026, so interested parties should speak up soon!